Clinical Trial Update: SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SHR-1701 in combination with stereotactic body radiotherapy for metastatic castration-resistant prostate cancer is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• SHR-1701

Snippet

Sponsor: Fudan University | Conditions: Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Status: RECRUITING